MEDP insider sales at $605.12 and $585 after option exercises

Rhea-AI Filing Summary

Medpace Holdings (MEDP) disclosed insider transactions by President Jesse J. Geiger. On 10/27/2025, he exercised 19,460 stock options at $166.73 per share and sold 19,460 shares at a $605.12 weighted average price, with trades ranging from $600.00 to $610.66. On 10/29/2025, he exercised an additional 3,568 options at $166.73 and sold 3,568 shares at $585.

The option was reported as having vested in full on October 27, 2025. Following the transactions, 36,503 shares were reported as beneficially owned directly. The filing notes the sales were effected pursuant to a limit order placed during an open window period.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GEIGER JESSE J

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OH 45227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
10/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/27/2025		M		19,460	A	$166.73	55,963	D
Common Stock	10/27/2025		S(1)		19,460	D	$605.12(2)	36,503	D
Common Stock	10/29/2025		M		3,568	A	$166.73	40,071	D
Common Stock	10/29/2025		S(1)		3,568	D	$585	36,503	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$166.73	10/27/2025		M			19,460	(3)	10/27/2026	Common Stock	19,460	$0	3,568	D
Employee Stock Option (Right to Buy)	$166.73	10/29/2025		M			3,568	(3)	10/27/2026	Common Stock	3,568	$0	0	D

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.00 to $610.66. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

3. The option vested in full on October 27, 2025.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for Jesse J. Geiger	10/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did MEDP report?

The President exercised options and sold shares: 19,460 exercised and sold on 10/27/2025, and 3,568 exercised and sold on 10/29/2025.

At what prices were MEDP shares sold?

On 10/27/2025, shares were sold at a $605.12 weighted average (range $600.00–$610.66). On 10/29/2025, shares were sold at $585.

What was the option exercise price for MEDP?

Both option exercises were at an exercise price of $166.73 per share.

How many MEDP shares does the insider hold after these trades?

Following the reported transactions, 36,503 shares were beneficially owned directly.

Did the MEDP option vesting occur before sales?

Yes. The option was reported as having vested in full on October 27, 2025.

Were the MEDP sales under a 10b5-1 plan?

The filing states the sales were effected pursuant to a limit order placed during an open window period; it does not state a 10b5-1 plan.

Who is the reporting person for these MEDP transactions?

Jesse J. Geiger, MEDP’s President, as indicated by the officer title and signature block.